NP-001 (Novabio Therapeutics)

人自体多克隆调节性T细胞

Report date: 2026/04/20 20:01:59

Base Information

Drug NameNP-001 (Novabio Therapeutics)
Drug Alias NameAutologous Human Polyclonal Regulatory T Cells Injection自体人多克隆调节性T细胞NP001 Cell InjectionNP-001
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs
Mechanisms of ActionRegulatory T-lymphocytes replacements
TargetsUpdating
Therapy Area/IndicationsMuscular Atrophy, SpinalAmyotrophic Lateral SclerosisMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovabio Therapeutics Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNovabio Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, SpinalAmyotrophic Lateral SclerosisMultiple System Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A